The VICL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VICL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The VICL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View VICL Detailed Price Forecast - CNN Money||View VICL Detailed Summary - Google Finance|
|View VICL Detailed Summary - Yahoo! Finance||View VICL Stock Research & Analysis - Zacks.com|
|View VICL Trends & Analysis - Trade-Ideas||View VICL Major Holders - Barrons|
|View VICL Call Transcripts - NASDAQ||View VICL Breaking News & Analysis - Seeking Alpha|
|View VICL Annual Report - CompanySpotlight.com||View VICL OTC Short Report - OTCShortReport.com|
|View VICL Fundamentals - TradeKing||View VICL SEC Filings - Bar Chart|
|View Historical Prices for VICL - The WSJ||View Performance/Total Return for VICL - Morningstar|
|View the Analyst Estimates for VICL - MarketWatch||View the Earnings History for VICL - CNBC|
|View the VICL Earnings - StockMarketWatch||View VICL Buy or Sell Recommendations - MacroAxis|
|View the VICL Bullish Patterns - American Bulls||View VICL Short Pain Metrics - ShortPainBot.com|
|View VICL Stock Mentions - StockTwits||View VICL Stock Mentions - PennyStockTweets|
|View VICL Stock Mentions - Twitter||View VICL Investment Forum News - Investor Hub|
|View VICL Stock Mentions - Yahoo! Message Board||View VICL Stock Mentions - Seeking Alpha|
|View Insider Transactions for VICL - SECform4.com||View Insider Transactions for VICL - Insider Cow|
|View VICL Major Holdings Summary - CNBC||View Insider Disclosure for VICL - OTC Markets|
|View Insider Transactions for VICL - Yahoo! Finance||View Institutional Holdings for VICL - NASDAQ|
|View VICL Stock Insight & Charts - FinViz.com||View VICL Investment Charts - StockCharts.com|
|View VICL Stock Overview & Charts - BarChart||View VICL User Generated Charts - Trading View|
Vical Announces Review of Potential Strategic Transactions
Posted on Thursday July 19, 2018
Vical Incorporated (VICL) today announced that its Board of Directors plans to explore a range of strategic options to enhance shareholder value. The company has retained MTS Health Partners, L.P. as its financial advisor to assist in the strategic review process. Vical is currently developing its novel anti-fungal drug VL-2397, which is currently in a Phase 2 clinical trial, and, in addition, has a preclinical program focused on a novel approach to chronic HBV infections.
When Will Vical Incorporated (NASDAQ:VICL) Become Profitable?
Posted on Wednesday June 27, 2018
Vical Incorporated’s (NASDAQ:VICL): Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.Read More...
Vical to scrap genital herpes treatment program after trial fails primary endpoint
Posted on Monday June 11, 2018
Vical Inc. said Monday a phase 2 trial of its treatment for genital herpes failed to meet its primary endpoint of annualized lesion recurrence rate. In a study of 261 healthy adults with herpes simplex virus type 2, aged 18 to 50, with a self-reported history of 4 to 9 recurrences a year, Vical said the annualized recurrence rate in the placebo group was "far less" than what was expected, meaning there was "significantly less power" to show a vaccine effect in the trial. "We are extremely disappointed with the outcome and based upon these results, we will be terminating the HSV-2 program," said Chief Executive Vijay Samant.
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
Posted on Monday June 11, 2018
Vical Incorporated (VICL) today announced top-line results from a randomized, double-blind, placebo-controlled, Phase 2 clinical study of its therapeutic bivalent vaccine candidate for herpes simplex virus type 2 (HSV-2), the leading cause of recurrent genital herpes. The Phase 2 study was conducted in 261 healthy HSV-2 seropositive adults, 18 to 50 years of age, with a self-reported history of 4 to 9 recurrences per year. “We took careful measures to recruit patients with self-reported history of 4 to 9 recurrences annually.